Persistence of Second and Third-Line Biologics in Inflammatory Bowel Disease: A Multi-Centre Cohort Study

Persistence of Second and Third-Line Biologics in Inflammatory Bowel Disease: A Multi-Centre Cohort Study

Background: Despite proven efficacy of biologics in inflammatory bowel disease (IBD), many exhibit primary non-response or secondary loss of response and switch to subsequent biologic(s). Here, we identified early predictors of second- and/or third-line biologic persistence in IBD, in a real-world c...

Full description

Bibliographic Details
Main Authors: Timothy P. Hanrahan, Robbie Chan, Daniel Tassone, Nik S. Ding, Chamara Basnayake, Julien Schulberg, Abhinav Vasudevan, Michael Kamm, Michael De Gregorio, Daniel R. van Langenberg, Ola Niewiadomski
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Future Pharmacology
Subjects:
Crohn’s disease
ulcerative colitis
infliximab
biologics
persistence
Online Access:https://www.mdpi.com/2673-9879/2/4/41

Similar Items

Similar Items